Lantheus Holdings [LNTH] vs Amneal [AMRX] Detailed Stock Comparison

Lantheus Holdings Inc.

NASDAQ
Loading...

Amneal Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Lantheus Holdings Inc. wins in 14 metrics, Amneal Pharmaceuticals Inc. wins in 6 metrics, with 0 ties. Lantheus Holdings Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Lantheus Holdings Inc. Amneal Pharmaceuticals Inc. Better
P/E Ratio (TTM) 24.30 63.23 Lantheus Holdings Inc.
Price-to-Book Ratio 4.91 -57.42 Lantheus Holdings Inc.
Debt-to-Equity Ratio 57.19 45,095.52 Lantheus Holdings Inc.
PEG Ratio -0.04 -0.30 Lantheus Holdings Inc.
EV/EBITDA 14.70 10.64 Amneal Pharmaceuticals Inc.
Profit Margin (TTM) 15.15% 2.39% Lantheus Holdings Inc.
Operating Margin (TTM) 19.07% 14.06% Lantheus Holdings Inc.
EBITDA Margin (TTM) 19.07% 14.06% Lantheus Holdings Inc.
Return on Equity 21.45% -101.02% Lantheus Holdings Inc.
Return on Assets (TTM) 9.28% 7.32% Lantheus Holdings Inc.
Free Cash Flow (TTM) $348.64M $225.64M Lantheus Holdings Inc.
1-Year Return 31.42% 79.92% Amneal Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 3.50 1.47 Amneal Pharmaceuticals Inc.
Enterprise Value $5.62B $6.86B Amneal Pharmaceuticals Inc.
EV/Revenue Ratio 3.65 2.27 Amneal Pharmaceuticals Inc.
Gross Profit Margin (TTM) 59.21% 36.50% Lantheus Holdings Inc.
Revenue per Share (TTM) $23 $10 Lantheus Holdings Inc.
Earnings per Share (Diluted) $3.41 $0.22 Lantheus Holdings Inc.
Beta (Stock Volatility) -0.13 1.32 Lantheus Holdings Inc.
Short % of Float 10.95% 3.47% Amneal Pharmaceuticals Inc.

Lantheus Holdings Inc. vs Amneal Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

LNTH
AMRX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Lantheus Holdings Inc.-0.85%-3.76%9.71%26.21%64.47%43.15%
Amneal Pharmaceuticals Inc.1.82%-1.09%-3.51%-8.13%5.42%-0.08%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Lantheus Holdings Inc.31.42%11.99%303.82%4,393.21%1,444.32%1,444.32%
Amneal Pharmaceuticals Inc.79.92%416.47%141.21%-10.41%-10.41%-10.41%

Performance & Financial Health Analysis: Lantheus Holdings Inc. vs Amneal Pharmaceuticals Inc.

MetricLNTHAMRX
Market Information
Market Cap i$5.39B$4.15B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i641,3341,402,990
90 Day Avg. Volume i839,5681,913,723
Last Close$96.30$12.88
52 Week Range$47.25 - $103.89$7.07 - $15.42
% from 52W High-7.31%-16.47%
All-Time High$126.89 (Jul 15, 2024)$24.48 (Aug 20, 2018)
% from All-Time High-24.11%-47.39%
Growth Metrics
Quarterly Revenue Growth0.04%0.12%
Quarterly Earnings Growth0.04%0.11%
Financial Health
Profit Margin (TTM) i0.15%0.02%
Operating Margin (TTM) i0.19%0.14%
Return on Equity (TTM) i0.21%-1.01%
Debt to Equity (MRQ) i57.1945,095.52
Cash & Liquidity
Book Value per Share (MRQ)$16.87$-0.23
Cash per Share (MRQ)$5.56$0.91
Operating Cash Flow (TTM) i$390.14M$339.99M
Levered Free Cash Flow (TTM) i$265.57M$197.07M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Lantheus Holdings Inc. vs Amneal Pharmaceuticals Inc.

MetricLNTH (Apr 24, 2026)AMRX (Apr 22, 2026)
Price Ratios
P/E Ratio (TTM) i24.3063.23
Forward P/E i13.1711.78
PEG Ratio i-0.04-0.30
Price to Sales (TTM) i3.501.47
Price to Book (MRQ) i4.91-57.42
Market Capitalization
Market Capitalization i$5.39B$4.15B
Enterprise Value i$5.62B$6.86B
Enterprise Value Metrics
Enterprise to Revenue i3.652.27
Enterprise to EBITDA i14.7010.64
Risk & Other Metrics
Beta i-0.131.32
Book Value per Share (MRQ) i$16.87$-0.23

Financial Statements Comparison: Lantheus Holdings Inc. vs Amneal Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLNTH (2025)AMRX (2025)
Revenue/Sales i1.54B3.02B
Cost of Goods Sold i599.66M1.91B
COGS % of Revenue i38.9%63.1%
Gross Profit i941.95M1.11B
Gross Margin i61.1%36.9%
Research & Development i177.31M193.81M
Operating Income (EBIT) i315.56M397.91M
Operating Margin i20.5%13.2%
EBITDA i409.00M606.64M
EBITDA Margin i26.5%20.1%
Pre-Tax Income i313.79M139.21M
Pre-Tax Income % of Revenue i20.4%4.6%
Income Tax i80.23M11.28M
Income Tax % of Revenue i5.2%0.4%
Net Income (Profit) i233.56M127.93M
Profit Margin i15.2%4.2%

Balance Sheet & Liquidity Metrics

MetricLNTH (2025)AMRX (2025)
Cash & Equivalents i359.12M282.03M
Total Current Assets i899.96M1.91B
Total Current Assets % of Revenue i58.4%63.3%
Total Current Liabilities i333.42M881.63M
Total Current Liabilities % of Revenue i21.6%29.2%
Long-Term Debt i618.69M2.67B
Long-Term Debt % of Revenue i40.1%88.4%
Total Shareholders Equity i1.09B-71.33M
Retained Earnings i679.50M-535.01M
Retained Earnings % of Revenue i44.1%-17.7%
Property, Plant & Equipment i30.98M107.38M

Cash Flow Statement Comparison

MetricLNTH (2025)AMRX (2025)
Operating Cash Flow i398.13M256.93M
Operating Cash Flow % of Revenue i25.8%8.5%
Capital Expenditures iN/A-96.75M
Free Cash Flow i348.64M225.64M
FCF Margin i22.6%7.5%
Debt Repayment i-1.11M-2.81B
Common Stock Repurchase i-300.02MN/A

Short Interest & Institutional Ownership Analysis

MetricLNTHAMRX
Shares Short i5.36M7.19M
Short Ratio i4.603.18
Short % of Float i10.95%3.47%
Shares Outstanding i64.59M314.57M
Float Shares i58.18M176.28M
% Held by Insiders i2.04%44.04%
% Held by Institutions i109.34%49.74%
% Held by Public i-11.38%6.22%

Dividend Analysis & Yield Comparison: Lantheus Holdings Inc. vs Amneal Pharmaceuticals Inc.

MetricLNTHAMRX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A